NEUROLOGICAL IMPLANTS SHOULD UNDERGO SPECIFIC BIOCOMPATIBILITY TESTS
This article was originally published in The Gray Sheet
Executive Summary
NEUROLOGICAL IMPLANTS SHOULD UNDERGO SPECIFIC BIOCOMPATIBILITY TESTS, FDA's Neurological Devices Advisory Panel suggested during a Sept. 16 meeting in Gaithersburg, Maryland. "The brain has to be looked at for its unique and multiple characteristics," said panel member Roger Contee, MD, Robert Wood Johnson Medical School, New Brunswick, New Jersey. "I think we need to study [implantation] in more detail...because of the very variegated effects" which materials can have on the brain.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.